Zoetis Inc - Class A
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees.
Trading 82% below its estimated fair value of $207.59.
Current Price
$114.16
-0.70%GoodMoat Value
$207.59
81.8% undervaluedZoetis Inc - Class A (ZTS) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Zoetis Inc - Class A's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $9.47B. Gross profit (TTM) is $6.80B. EBITDA is $4.07B. Earnings per share (EPS) is $6.02. The P/E ratio is 18.82. Market capitalization is $50.31B.
Free cash flow (FCF) is $2.28B. FCF growth rate is 9.07%. EPS growth CAGR is 10.11%. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Zoetis Inc - Class A's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
